방광암 : 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(2025-2035년)

Bladder Cancer Market Outlook

Thelansis's "Bladder Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bladder Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Bladder Cancer Overview

Bladder cancer is the most common malignancy of the urinary tract, with urothelial carcinoma representing the predominant histological subtype, arising from the transitional epithelium lining the bladder mucosa. Tobacco smoking, occupational aromatic amine exposure, chronic bladder inflammation, and cyclophosphamide exposure are established risk factors, with somatic mutations in FGFR3, TP53, RB1, and PIK3CA driving oncogenic transformation across non-muscle-invasive and muscle-invasive disease spectrums. Patients present with painless macroscopic haematuria - the cardinal symptom - alongside urinary frequency, urgency, and dysuria; cystoscopy with biopsy remains the diagnostic gold standard, supplemented by upper tract imaging and CT urography. Non-muscle-invasive bladder cancer is managed endoscopically via transurethral resection, with intravesical BCG immunotherapy reducing recurrence and progression risk in high-risk disease; pembrolizumab is approved for BCG-unresponsive carcinoma in situ. Muscle-invasive disease warrants neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy or bladder-preserving trimodality therapy. Metastatic disease is addressed with platinum-based chemotherapy, while maintenance avelumab immunotherapy following platinum response has demonstrated meaningful survival benefit. Erdafitinib targets FGFR3-altered metastatic disease, and enfortumab vedotin - a Nectin-4 directed antibody-drug conjugate - alongside pembrolizumab represents a transformative first-line metastatic standard. Prognosis varies with stage; multidisciplinary management, surveillance cystoscopy, and patient-centred quality-of-life optimisation are integral to long-term care.

Key Highlights

• In Germany, survival-adjusted prevalent Bladder Cancer cases are projected to increase from 727,014 in 2025 to 777,528 by 2035.
• Rising aging population and smoking-related risk burden continue to drive disease prevalence.
• Increasing adoption of immunotherapies and targeted agents is reshaping the treatment landscape.
• Persistent unmet need exists in advanced and recurrent bladder cancer management.

Market Overview

• The Italy Bladder Cancer market is projected to grow from USD 420 million in 2025 to USD 990 million by 2035.
• Market growth is driven by increasing uptake of immuno-oncology therapies and improved diagnosis rates.
• Future expansion will depend on advances in targeted therapies and combination treatment strategies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Merck Sharp & Dohme LLC
• Ferring Pharmaceuticals
• ImmunityBio, Inc.
• Lipac Oncology LLC
• Daiichi Sankyo
• UroGen Pharma Ltd.
• CG Oncology, Inc.
• Astellas Pharma Global Development, Inc.
• Zhuhai Beihai Biotech Co., Ltd.
• ALX Oncology Inc.
• Hoffmann-La Roche
• Protara Therapeutics
• Monopar Therapeutics
• Eli Lilly and Company
• Incyte Corporation
• ViroMissile, Inc.
• Genentech, Inc.
• Palleon Pharmaceuticals, Inc.
• NGM Biopharmaceuticals, Inc.
• Toray Industries, Inc.
• BeiGene
• Arcus Biosciences, Inc.
• AstraZeneca
• Sensei Biotherapeutics, Inc.
• Beijing Biotech
• OncoC4, Inc.
• MacroGenics
• Pfizer
• OncoNano Medicine, Inc.
• Medicenna Therapeutics, Inc.
• EvolveImmune United, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)